Works matching IS 17762596 AND DT 2021 AND VI 16 AND IP 6
Results: 16
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 813, doi. 10.1007/s11523-021-00852-z
- By:
- Publication type:
- Article
Acknowledgement to Referees.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 697, doi. 10.1007/s11523-021-00851-0
- Publication type:
- Article
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 789, doi. 10.1007/s11523-021-00850-1
- By:
- Publication type:
- Article
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 761, doi. 10.1007/s11523-021-00849-8
- By:
- Publication type:
- Article
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 801, doi. 10.1007/s11523-021-00848-9
- By:
- Publication type:
- Article
Correction to: Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Isatuximab: A Review of Its Use in Multiple Myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 753, doi. 10.1007/s11523-021-00845-y
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 743, doi. 10.1007/s11523-021-00844-z
- By:
- Publication type:
- Article
Durvalumab: A Review in Extensive-Stage SCLC.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 857, doi. 10.1007/s11523-021-00843-0
- By:
- Publication type:
- Article
Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 847, doi. 10.1007/s11523-021-00842-1
- By:
- Publication type:
- Article
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 839, doi. 10.1007/s11523-021-00841-2
- By:
- Publication type:
- Article
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 701, doi. 10.1007/s11523-021-00838-x
- By:
- Publication type:
- Article
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 773, doi. 10.1007/s11523-021-00833-2
- By:
- Publication type:
- Article
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 823, doi. 10.1007/s11523-021-00831-4
- By:
- Publication type:
- Article